SRR6013541
— · cohortSQ1
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortSQ1
- subtype
- cohortSQ1
GSVA pathway preview (0 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
6 twins match this tumor's tissue · 4 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MDT-AP-3189 | Med | Medulloblastoma | 0.915 |
| 2 | BS_JT82QGXF | medulloblastoma | — | 0.912 |
| 3 | BS_YMAJC22S | low-grade glioma | — | 0.907 |
| 4 | MNG1257 | — | — | 0.904 |
| 5 | MNG189 | — | — | 0.900 |
| 6 | SRR23303774 | — | — | 0.899 |
| 7 | SRR1797291 | — | cohortSC | 0.892 |
| 8 | BS_Q13FQ8FV | Diffuse intrinsic pontine glioma | — | 0.891 |
| 9 | SRR22247242 | — | cohortSC | 0.890 |
| 10 | TCGA-56-A5DS-01A-11R-A27Q-07 | — | cohortSQ1 | 0.888 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 9 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| KRAS_SIGNALING_DN | 0.340 | Remibrutinib | — uncovered |
| E2F_TARGETS | 0.230 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.220 | Temsirolimus | — uncovered |
| G2M_CHECKPOINT | 0.210 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.190 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.170 | Cobimetinib | — uncovered |
| HEDGEHOG_SIGNALING | 0.120 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.110 | Idelalisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.080 | Inavolisib | — uncovered |